GLSI vs. CRMD, SION, ORGO, ABUS, SANA, CDXC, KALV, MGTX, PHAR, and ARVN
Should you be buying Greenwich LifeSciences stock or one of its competitors? The main competitors of Greenwich LifeSciences include CorMedix (CRMD), Sionna Therapeutics (SION), Organogenesis (ORGO), Arbutus Biopharma (ABUS), Sana Biotechnology (SANA), ChromaDex (CDXC), KalVista Pharmaceuticals (KALV), MeiraGTx (MGTX), Pharming Group (PHAR), and Arvinas (ARVN). These companies are all part of the "pharmaceutical products" industry.
Greenwich LifeSciences vs.
CorMedix (NASDAQ:CRMD) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation, community ranking and earnings.
Greenwich LifeSciences has lower revenue, but higher earnings than CorMedix. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.
In the previous week, CorMedix had 17 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 18 mentions for CorMedix and 1 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 1.87 beat CorMedix's score of 0.91 indicating that Greenwich LifeSciences is being referred to more favorably in the news media.
34.2% of CorMedix shares are held by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are held by institutional investors. 5.2% of CorMedix shares are held by company insiders. Comparatively, 51.7% of Greenwich LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
CorMedix has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, Greenwich LifeSciences has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500.
CorMedix's return on equity of -79.21% beat Greenwich LifeSciences' return on equity.
CorMedix currently has a consensus price target of $16.00, suggesting a potential upside of 117.98%. Greenwich LifeSciences has a consensus price target of $38.00, suggesting a potential upside of 256.81%. Given Greenwich LifeSciences' higher probable upside, analysts plainly believe Greenwich LifeSciences is more favorable than CorMedix.
CorMedix received 22 more outperform votes than Greenwich LifeSciences when rated by MarketBeat users. Likewise, 78.95% of users gave CorMedix an outperform vote while only 44.44% of users gave Greenwich LifeSciences an outperform vote.
Summary
CorMedix beats Greenwich LifeSciences on 11 of the 17 factors compared between the two stocks.
Get Greenwich LifeSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Greenwich LifeSciences Competitors List
Related Companies and Tools
This page (NASDAQ:GLSI) was last updated on 3/26/2025 by MarketBeat.com Staff
Buy GLSI Stock Free GLSI Stock Alerts